<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EC6FA051-95A6-49A6-A59F-83F91DF7F679"><gtr:id>EC6FA051-95A6-49A6-A59F-83F91DF7F679</gtr:id><gtr:firstName>Maria</gtr:firstName><gtr:surname>Hawkins</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12001%2F2"><gtr:id>879CC539-B191-45E8-8CD4-A8D3DEA84B21</gtr:id><gtr:title>Exploring novel solutions of radiotherapy delivery and using biological imaging, new fractionations and radiobiological models to improve TCP/NTCP ratio</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12001/2</gtr:grantReference><gtr:abstractText>Cancers of the upper gastro-intestinal tract (oesophagus, pancreas) have a poor outcome if surgery cannot be undertaken. Radical radiotherapy combined with chemotherapy are the standard of care, however a significant number of patients have tumour recurrence in the radiotherapy field. In the past increasing radiotherapy dose caused severe toxicity. There are now several technological advances in radiotherapy that permits further individualization of treatment using either functional imaging such as MRI and PET to guide the areas that need more radiotherapy or focused radiotherapy (such as Stereotactic ablative radiotherapy) to areas of tumour that cannot be removed by surgery.
The aim of the research is to further personalise the way radiotherapy is delivered using characteristics specific to an individual patient and/or tumour. The ultimate impact in clinical practice would be improvement in local tumour control and reduction in toxicity caused by radiation.</gtr:abstractText><gtr:technicalSummary>Despite several advances in techniques of radiotherapy planning (intensity modulated radiotherapy (IMRT), tumour imaging (PET, MRI); radiation delivery (rotational arc therapy, flattening filter free), image guided radiotherapy (IGRT), the techniques and doses used for radiotherapy treatments of gastro-intestinal malignancies cancers have remained unchanged. The outcomes of patients with tumours such as oesophagus; treated with chemo-radiotherapy in the radical setting have not improved over the last decades with local failure (in the radiotherapy target volume) being predominant. The causes of local failure are due to several aspects: inadequate radiation dose, hypoxia, failure to target areas that have an unfavourable micro-environment. The advances in technology offer an opportunity to explore novel approaches.
The aim of my research has 3 main themes with the ultimate aim of maximising clinical benefit in terms of better tumour control and reduction in toxicity. 
1. Strategies of modulating radiotherapy (SMART). Radiotherapy dose escalation techniques using Simultaneous Integrated Boost (SIB) permits intensification of radiotherapy dose to predetermined volumes of the highly conformal target volume e.g. Tumour control probability/ normal tissue control probability (TCP/NTCP) models can be then used to refine the escalation further. The SIB could be derived from biological imaging such as PET or functional MRI. These techniques can incorporate imaging as a biomarker for outcome and toxicity with the aim to individualise dose and fractionation delivered. Combination with biological agents would be tested to further improve the therapeutic ratio.
2. Margin intense therapy concept. The use of stereotactic ablative radiotherapy to areas at risk of positive margin at surgery with the aim of achieving complete tumour resection in tumours such as pancreatic cancers.
3. Refining normal tissue toxicity modelling in thoracic malignancies. The objective of this work would be to characterise and corroborate lung, heart and oesophagus radiotherapy toxicity parameters and develop individualised RT delivery techniques to mitigate dose to susceptible cardiac and or lung substructures. Develop patient selection and specific cardiopulmonary optimisation when multimodality approach such as chemo-radiation followed by surgery is required. Novel MRI techniques would be tested to characterise changes and aid develop patient specific RT delivery.</gtr:technicalSummary><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1681000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Refining the normal tissue parameters for radiotherapy treatments in lung cancer</gtr:description><gtr:id>7052E427-7996-4D85-A0C8-122FE5A4B8EC</gtr:id><gtr:impact>abstracts and oral presentations at international meetings</gtr:impact><gtr:outcomeId>56ddcda784b752.42054166-2</gtr:outcomeId><gtr:partnerContribution>provided data (UCL)
stats support (Liverpool)</gtr:partnerContribution><gtr:piContribution>data analysis of radiotherapy delivered part of a CRUK funded trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Refining the normal tissue parameters for radiotherapy treatments in lung cancer</gtr:description><gtr:id>11692858-7E7B-4899-9AB2-3B798F58F3E2</gtr:id><gtr:impact>abstracts and oral presentations at international meetings</gtr:impact><gtr:outcomeId>56ddcda784b752.42054166-1</gtr:outcomeId><gtr:partnerContribution>provided data (UCL)
stats support (Liverpool)</gtr:partnerContribution><gtr:piContribution>data analysis of radiotherapy delivered part of a CRUK funded trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wales Cancer Trials Unit</gtr:department><gtr:description>Refining radiotherapy in oesophageal cancer</gtr:description><gtr:id>CDE9C531-F12C-4776-B5A9-A4B4E64B6683</gtr:id><gtr:impact>Early collaboration so abstract submitted to ESTRO 2014 and manuscript published
Trial successfully funded by CTAAC</gtr:impact><gtr:outcomeId>cGMJxMVurPi-1</gtr:outcomeId><gtr:partnerContribution>provided database and data interpretation, visiting PhD student</gtr:partnerContribution><gtr:piContribution>developed radiotherapy dose escalation models estimating improvement in outcomes for definitive chemo radiation in inoperable oesophageal cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>A Witztum_Oxford Science Fair (Jun 2016)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CF74AC25-DA44-4258-9B05-E4D26FCA7957</gtr:id><gtr:impact>presenting public opportunities and challenges in undertaking basic research</gtr:impact><gtr:outcomeId>577a660992d7a7.53819292</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pancreatic Cancer UK Anniversary Event (Feb 2016)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0D753654-21F5-4679-BE85-31DEFD198624</gtr:id><gtr:impact>The event celebrated 10 years of PCUK charity work and highlighted the research and other improvements made in pancreatic cancer</gtr:impact><gtr:outcomeId>577a670a936a70.97365239</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk re: stereotactic radiotherapypancreatic cancer</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A427DD21-ADC7-413D-BB0E-3BD78B39492C</gtr:id><gtr:impact>Pancreatic Cancer UK Summit on Survival
Stereotactic body radiotherapy in pancreatic cancer

Discussion re access to novel radiotherapy techniques</gtr:impact><gtr:outcomeId>Roz9Pik8wXK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.pancreaticcancer.org.uk/campaigning/annual-summit/2013-summit-on-survival</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>D Holyoake_CRUK Shine Night Walk 2016 &quot;Thank-you&quot; video (national coverage) (2016)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FD99DC6F-9C7F-48AF-AFE2-C3D9F74644E2</gtr:id><gtr:impact>video to thank supporters and participants to a CRUK event</gtr:impact><gtr:outcomeId>582da2a5134c45.49639720</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=JEgfhwV1D_Y</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>L Bendall_MRC festival of medical research roadshow (UK, June)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>552974A2-CB07-46A1-BC6D-6718AF84914D</gtr:id><gtr:impact>Louise helped out during the MRC science festival. She spent the day in Banbury as part of the MRC festival of medical research roadshow around Oxford. It aimed to engage with the public and explain to them some of the research currently undertaken by the MRC in the &amp;quot;fight against cancer&amp;quot; using the immune system. I did the Banbury stint, but the outings aimed to reach members of the public in and around Oxford (particularly small local towns).</gtr:impact><gtr:outcomeId>577a65cfe33d29.83725327</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>M Hawkins_reviewing Macmillan Cancer Support's booklet on Understanding primary liver cancer</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>872BB0E7-0A97-4005-812A-0521D5E441CB</gtr:id><gtr:impact>Received a request from Macmillan Cancer Support to review/comment on their booklet &amp;quot;Understanding primary liver cancer&amp;quot; as a specialist reviewer.</gtr:impact><gtr:outcomeId>5832d35b6605b3.60294424</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK Grand Challenge Meeting (London, Jan 2015)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>70CB8DA3-A05E-4D78-99C1-B77063FA9136</gtr:id><gtr:impact>brainstorming meeting to propose research idea for forthcoming CRUK grand challenge proposal</gtr:impact><gtr:outcomeId>569f70d7df12a4.74285319</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>13555316</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ATR inhibitor and radiotherapy in oesophageal cancer Phase I trial (CHARIOt)</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C43735/A20874</gtr:fundingRef><gtr:id>CECE627A-D36C-4BA5-9E5C-58D795B24B8B</gtr:id><gtr:outcomeId>56d03acb037312.81265663</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>SABR Consortium Radiotherapy Guidance</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F01A0658-7657-4647-907F-2F75900C9634</gtr:id><gtr:outcomeId>54627480e1d5f5.41935435</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>IMRT implementation for anal cancer radical radiotherapy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3C10E4BB-61FC-4371-AA39-6753FD0C12D8</gtr:id><gtr:impact>the uptake in IMRT and related outcomes for anal cancer was audited by the Royal College of Radiologists Q4 2015. the results of the audit will hopefully confirm outcomes.</gtr:impact><gtr:outcomeId>Z3zoqQB3n3X</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>IMRT Foundation Workshop RCR</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C0CFD0E3-FF74-4E7F-B4BE-0749C70979E0</gtr:id><gtr:impact>Improvement of radiotherapy technique delivery with a reduction in morbidity of treatment</gtr:impact><gtr:outcomeId>DZp9hKCecJi</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>TBA</gtr:description><gtr:id>6967F629-50E3-4F4A-A2A4-331928526F6B</gtr:id><gtr:impact>TBA</gtr:impact><gtr:outcomeId>58b80a1da60109.92554661</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Clinical Trial: CORE Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>TBA</gtr:description><gtr:id>15F83EFF-40F3-43C4-9AFA-FEB5F021A28C</gtr:id><gtr:impact>TBA</gtr:impact><gtr:outcomeId>58b809db374cd1.16050921</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Clinical trial: SCOPE2 -  Study of chemoradiotherapy in oesophageal cancer including PET response and dose escalation</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>CRUK funded trial</gtr:description><gtr:id>81CA03DA-2E55-4D98-828C-4AA757F1BF1D</gtr:id><gtr:impact>none at present</gtr:impact><gtr:outcomeId>56a23387415d80.55938806</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers(Cancer Research UK &amp; UCL Cancer Trials Centre)</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>phase I trial to find the maximum tolerated dose of margin intense stereotactic ablation radiotherapy for borderline resectable pancreatic cancer</gtr:description><gtr:id>29EB8D01-2690-473B-B1D6-9BF89E94697D</gtr:id><gtr:impact>trial ongoing</gtr:impact><gtr:outcomeId>56a231bdce0139.30979213</gtr:outcomeId><gtr:status>Under active development/distribution</gtr:status><gtr:title>Clinical Trial_SBRT pre-operatively for borderline resectable pancreatic cancer (OCTO)</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:url>http://www.oncology.ox.ac.uk/trial/sparc</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>TBA</gtr:description><gtr:id>F8470C9F-6A73-407F-9344-7AB7068454E4</gtr:id><gtr:impact>TBA</gtr:impact><gtr:outcomeId>58b8095130a907.79443078</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Clinical Trial: PLATO - Parsonalising Anal Cancer Radiotherapy Dose</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7990FE2E-8E11-48A1-8655-DEFBA298A8C9</gtr:id><gtr:title>PD-0526: Robustness of integrated boost plans for oesophageal cancer: arctherapy vs intensity-modulated proton therapy</gtr:title><gtr:parentPublicationTitle>Radiotherapy and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f822086bb4508bdbae8e47200941e6bc"><gtr:id>f822086bb4508bdbae8e47200941e6bc</gtr:id><gtr:otherNames>Warren S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a0bdde498cc9.13378129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82EB2B86-F6BA-4332-B524-6EE40BB98D75</gtr:id><gtr:title>Clinical development of new drug-radiotherapy combinations.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca7a5462f5e4503ad848595f417ef08f"><gtr:id>ca7a5462f5e4503ad848595f417ef08f</gtr:id><gtr:otherNames>Sharma RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>5821d19cb4c843.07566057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C768B52-C619-431A-86C0-286F293D8F92</gtr:id><gtr:title>Correlation ofF-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ffd4919451824364820657fe5fa13fe"><gtr:id>2ffd4919451824364820657fe5fa13fe</gtr:id><gtr:otherNames>Wilson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>59e5f8cf4624a4.77993852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D28A002-D195-444D-8AF3-987E6A2B3780</gtr:id><gtr:title>Evaluating Small Bowel Dose-Volume Tolerance Limits for SBRT Using a Preoperative Rectal Radiation Therapy Model: Are We Setting the Bar Too High?</gtr:title><gtr:parentPublicationTitle>International Journal of Radiation Oncology*Biology*Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bebe362687bf0d15de81b5f38e8b53b3"><gtr:id>bebe362687bf0d15de81b5f38e8b53b3</gtr:id><gtr:otherNames>Aitken K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56cb0897c22f78.29772658</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>601F0AC6-B63B-40B2-8F9A-46A5747D4E1A</gtr:id><gtr:title>Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): A systematic review.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8d4789bddcfc2a94dedff6fd2273418"><gtr:id>f8d4789bddcfc2a94dedff6fd2273418</gtr:id><gtr:otherNames>Murray LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5a6368410f0328.91254524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E800728E-FB6F-4FC4-87A5-962027D9AD70</gtr:id><gtr:title>Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy.</gtr:title><gtr:parentPublicationTitle>The American journal of clinical nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/490a9bd86c649d8dac591236e144ec46"><gtr:id>490a9bd86c649d8dac591236e144ec46</gtr:id><gtr:otherNames>Wedlake L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9165</gtr:issn><gtr:outcomeId>598b294dd27a12.93744101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C35FEFA-F0EE-4D37-A90A-5CEB546B399F</gtr:id><gtr:title>Risk-adapted strategy partial liver irradiation for the treatment of large volume metastatic liver disease.</gtr:title><gtr:parentPublicationTitle>Acta oncologica (Stockholm, Sweden)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9a0e40dc2ca1043ee8783b3e83506fe"><gtr:id>c9a0e40dc2ca1043ee8783b3e83506fe</gtr:id><gtr:otherNames>Aitken KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0284-186X</gtr:issn><gtr:outcomeId>5461e9bd0d2593.83625265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E0DE519-74E1-41E5-9883-1E8305E02CEC</gtr:id><gtr:title>EP-1470: Does gastric toxicity influence dose escalation in lower oesophageal tumours? A radiobiological investigation</gtr:title><gtr:parentPublicationTitle>Radiotherapy and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/922e827c7cceaa9857bcfc1ac7f6be29"><gtr:id>922e827c7cceaa9857bcfc1ac7f6be29</gtr:id><gtr:otherNames>Staffurth J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a0bd80d7b614.62464981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32A3C2C2-204F-4017-BB3F-F537C0DD4D7B</gtr:id><gtr:title>Abstract_Volumetric analysis of anal cancer relapses following radical chemoradiation</gtr:title><gtr:parentPublicationTitle>Journal of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eed8d902a99f5f922410822a358cf14c"><gtr:id>eed8d902a99f5f922410822a358cf14c</gtr:id><gtr:otherNames>Muirhead R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56a0ead1dbe154.94306339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68693596-FBE4-49F2-9ED8-FF161697F91A</gtr:id><gtr:title>Comparison of Acuros (AXB) and Anisotropic Analytical Algorithm (AAA) for dose calculation in treatment of oesophageal cancer: effects on modelling tumour control probability.</gtr:title><gtr:parentPublicationTitle>Radiation oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e17c4c50c94c89774aa1434572d3e6"><gtr:id>e0e17c4c50c94c89774aa1434572d3e6</gtr:id><gtr:otherNames>Padmanaban S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1748-717X</gtr:issn><gtr:outcomeId>doi_55faa2aa22533d6c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71065799-466F-410C-88C8-E34275DA67C6</gtr:id><gtr:title>Abstract_NeoSCOPE: A phase II randomized comparison of neoadjuvant oxaliplatin/capecitabine versus carboplatin/paclitaxel-based chemoradiation in operable esophageal cancer</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d74a67c0b16474cca84e6b31dbf4010"><gtr:id>6d74a67c0b16474cca84e6b31dbf4010</gtr:id><gtr:otherNames>Crosby T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56a0def8850b93.63110331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45CB8D77-8E42-408D-BA03-269369F4DDBB</gtr:id><gtr:title>Prognostic significance of blood transfusion and anaemia on survival in stage IIIA/B/C and IVA oesophageal cancers treated with chemoradiotherapy</gtr:title><gtr:parentPublicationTitle>Journal of Radiation Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bfc8f5e583f664a742c07bdbe9418f4"><gtr:id>1bfc8f5e583f664a742c07bdbe9418f4</gtr:id><gtr:otherNames>Tuan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461f5726533f4.99162807</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F83EA419-473C-4422-979D-252A50114F1F</gtr:id><gtr:title>Four-dimensional Computed Tomography Contouring Variability in Stereotactic Body Radiotherapy of Non-resectable Biliary Tract Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c349ab99087a0dcd1a400fc417f8e96"><gtr:id>8c349ab99087a0dcd1a400fc417f8e96</gtr:id><gtr:otherNames>Robinson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>590057f96f91b2.33797199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7021F4D4-A664-424B-AA1B-6C898994F53A</gtr:id><gtr:title>The Application of Pre and Post Chemoradiation Therapy FDG-PET/CT to Treatment Strategy Selection in Locally Advanced Pancreatic Cancer</gtr:title><gtr:parentPublicationTitle>INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58cc6801429013572fe44c67295533e7"><gtr:id>58cc6801429013572fe44c67295533e7</gtr:id><gtr:otherNames>Wilson J. M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>578796fb86c514.25091186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD1875FE-D8C2-47E7-8B90-F04F9FEF6682</gtr:id><gtr:title>WE-AB-202-10: Modelling Individual Tumor-Specific Control Probability for Hypoxia in Rectal Cancer</gtr:title><gtr:parentPublicationTitle>Medical Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f822086bb4508bdbae8e47200941e6bc"><gtr:id>f822086bb4508bdbae8e47200941e6bc</gtr:id><gtr:otherNames>Warren S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>5877830a95efe3.06947564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>240991E7-CDE4-4A4A-96CE-BD03C2403FA3</gtr:id><gtr:title>Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eed8d902a99f5f922410822a358cf14c"><gtr:id>eed8d902a99f5f922410822a358cf14c</gtr:id><gtr:otherNames>Muirhead R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5a7314efcaa730.09611069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97084EE4-6EEE-4F62-BABC-3D95B3920233</gtr:id><gtr:title>Unwrapping 3D complex hollow organs for spatial dose surface analysis.</gtr:title><gtr:parentPublicationTitle>Medical physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4eb6ff4c2a1ad14391659fb5de69530"><gtr:id>a4eb6ff4c2a1ad14391659fb5de69530</gtr:id><gtr:otherNames>Witztum A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0094-2405</gtr:issn><gtr:outcomeId>5a995db00035a7.97375769</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06FB136B-55C0-4E04-BBBD-2AE119379019</gtr:id><gtr:title>miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3359360a498b0c0af88fcb201686850c"><gtr:id>3359360a498b0c0af88fcb201686850c</gtr:id><gtr:otherNames>Khan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>577a772642a750.46652188</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7899D5C9-6351-4CBB-B7ED-14EF6B80F3DB</gtr:id><gtr:title>Stereotactic body radiotherapy for oligometastases</gtr:title><gtr:parentPublicationTitle>The Lancet Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77aa0242522e96ea9432261f46acc91d"><gtr:id>77aa0242522e96ea9432261f46acc91d</gtr:id><gtr:otherNames>Tree A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5461eead113440.09502029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>996D59CE-5031-4942-B303-54E2FFE0EDC5</gtr:id><gtr:title>Oral Contrast Improves Soft Tissue Matching in Image Guided Radiation Therapy for Gastrointestinal (GI) Tumors</gtr:title><gtr:parentPublicationTitle>International Journal of Radiation Oncology*Biology*Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9da1e41f28473e556d4091c8d0380686"><gtr:id>9da1e41f28473e556d4091c8d0380686</gtr:id><gtr:otherNames>Chu K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>58074b98a04f08.78853014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D38C18F4-DD90-4AC6-8E30-1033EB920CE9</gtr:id><gtr:title>The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3de01545b9f6611f5ad03831ab669ee2"><gtr:id>3de01545b9f6611f5ad03831ab669ee2</gtr:id><gtr:otherNames>Vivekanandan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>593168e0477577.43489622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75205E4B-42FA-4061-A5DB-6D1D7BA2CA10</gtr:id><gtr:title>ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)-Mechanism and clinical outcomes.</gtr:title><gtr:parentPublicationTitle>JOURNAL OF CLINICAL ONCOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ed5b9ba6de7a23aa6851163a7e3ae8b"><gtr:id>9ed5b9ba6de7a23aa6851163a7e3ae8b</gtr:id><gtr:otherNames>Wilson James Matthew</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>578797f004c031.68908209</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2037F9D2-4C73-4BBC-B583-01F12C0D8352</gtr:id><gtr:title>Intravenous contrast-enhanced cone beam computed tomography (IVCBCT) of intrahepatic tumors and vessels.</gtr:title><gtr:parentPublicationTitle>Advances in radiation oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a17c5933157303437325fc4610711a7c"><gtr:id>a17c5933157303437325fc4610711a7c</gtr:id><gtr:otherNames>Eccles CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2452-1094</gtr:issn><gtr:outcomeId>577a7769a9b4f5.91762153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>300BBC06-36CF-4D11-97CE-2E1F990B40DD</gtr:id><gtr:title>Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eed8d902a99f5f922410822a358cf14c"><gtr:id>eed8d902a99f5f922410822a358cf14c</gtr:id><gtr:otherNames>Muirhead R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5461e6cdc0c0e4.48478251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2463A5AE-62E2-4064-84CA-1DECBC983EC0</gtr:id><gtr:title>Prospective Review of Outlining in the UK NeoSCOPE Esophageal Trial</gtr:title><gtr:parentPublicationTitle>International Journal of Radiation Oncology*Biology*Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ee03beddac2c3f8b992e50f17cadc53"><gtr:id>3ee03beddac2c3f8b992e50f17cadc53</gtr:id><gtr:otherNames>Gwynne S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56cb04f29a1a98.47131117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D1D3FCC-6811-4308-AC59-8195F5D9CBCE</gtr:id><gtr:title>TH-AB-BRB-11: A Method of Unwrapping 3D Complex Hollow Organs for Spatial Dose Surface Analysis</gtr:title><gtr:parentPublicationTitle>Medical Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4eb6ff4c2a1ad14391659fb5de69530"><gtr:id>a4eb6ff4c2a1ad14391659fb5de69530</gtr:id><gtr:otherNames>Witztum A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a0bcbf0f9ac6.71071973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3033A2DE-975C-4454-8C40-B0EC336BC61E</gtr:id><gtr:title>Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c60c4f07b590f8fe1e7feacdba0e22e0"><gtr:id>c60c4f07b590f8fe1e7feacdba0e22e0</gtr:id><gtr:otherNames>Holyoake DLP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>59565e31429334.38386516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9738DD96-3DDA-44BA-924E-73172E8EA54B</gtr:id><gtr:title>EP-1632: Should dose escalation in oesophageal cancer be re-visited? A radiobiological analysis</gtr:title><gtr:parentPublicationTitle>Radiotherapy and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f822086bb4508bdbae8e47200941e6bc"><gtr:id>f822086bb4508bdbae8e47200941e6bc</gtr:id><gtr:otherNames>Warren S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56a0e4272fc437.82267377</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E083A0CE-DBEE-401D-88B6-30A58F691D5F</gtr:id><gtr:title>Challenges in using &amp;sup1;8F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Radiation oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ffd4919451824364820657fe5fa13fe"><gtr:id>2ffd4919451824364820657fe5fa13fe</gtr:id><gtr:otherNames>Wilson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1748-717X</gtr:issn><gtr:outcomeId>5461e711cf1c91.34182559</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>495982A9-C210-4D52-B5A4-A1B7AB5D4C6F</gtr:id><gtr:title>Stepwise Multicenter Introduction of Intensity Modulated Radiation Therapy for Anal Cancer in the United Kingdom: From Consensus Guidance to Large-Scale Prospective Audit, Prior to Future Clinical Trials</gtr:title><gtr:parentPublicationTitle>International Journal of Radiation Oncology*Biology*Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edd49c409010b2d19bb57944f97a9e69"><gtr:id>edd49c409010b2d19bb57944f97a9e69</gtr:id><gtr:otherNames>Gilbert D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>58074b985f5dc4.79562580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C758D013-A626-415E-8FA2-168DBFDB9635</gtr:id><gtr:title>Oesophageal Chemoradiotherapy in the UK--current practice and future directions.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ee03beddac2c3f8b992e50f17cadc53"><gtr:id>3ee03beddac2c3f8b992e50f17cadc53</gtr:id><gtr:otherNames>Gwynne S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5461ed2f80a130.82033028</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>729BEE41-3F77-4448-8488-85B47D42CA09</gtr:id><gtr:title>A Method of Unwrapping 3D Complex Hollow Organs for Spatial Dose Surface Analysis</gtr:title><gtr:parentPublicationTitle>MEDICAL PHYSICS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4522f64267618fe0eb4ff89c2325b71e"><gtr:id>4522f64267618fe0eb4ff89c2325b71e</gtr:id><gtr:otherNames>Witztum A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0094-2405</gtr:issn><gtr:outcomeId>578797c1ba2323.20666414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D0DCF84-82D6-4E81-B365-5E66BCC259E3</gtr:id><gtr:title>P-182 * Clinical outcomes of a phase II study of nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy in locally-advanced pancreatic cancer - functional imaging is prognostic and provides proof of mechanism</gtr:title><gtr:parentPublicationTitle>Annals of Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e72e51aacbce037a98004577c2bfe94f"><gtr:id>e72e51aacbce037a98004577c2bfe94f</gtr:id><gtr:otherNames>Wilson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56cb02f2ec77f2.00941871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3DE5AAD-296B-4B6F-833A-1C01069F70F3</gtr:id><gtr:title>SU-D-BRA-06: Duodenal Interfraction Motion with Abdominal Compression</gtr:title><gtr:parentPublicationTitle>Medical Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4eb6ff4c2a1ad14391659fb5de69530"><gtr:id>a4eb6ff4c2a1ad14391659fb5de69530</gtr:id><gtr:otherNames>Witztum A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>587782598e5ce8.87353315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81E212B8-A75B-46D0-9146-72818797D85B</gtr:id><gtr:title>A Tumor Control Probability Model for Anal Squamous Cell Carcinoma</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eed8d902a99f5f922410822a358cf14c"><gtr:id>eed8d902a99f5f922410822a358cf14c</gtr:id><gtr:otherNames>Muirhead R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56cb06e0e67010.30004279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FC43548-3268-4E73-9859-E2645DE4BB8C</gtr:id><gtr:title>Initial UK Experience of Stereotactic Body Radiotherapy for Extracranial Oligometastases: Can We Change the Therapeutic Paradigm?</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bebe362687bf0d15de81b5f38e8b53b3"><gtr:id>bebe362687bf0d15de81b5f38e8b53b3</gtr:id><gtr:otherNames>Aitken K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>56571c7c989db8.30364847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34749BBE-F457-460C-9C1B-88F2F53216A6</gtr:id><gtr:title>ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ffd4919451824364820657fe5fa13fe"><gtr:id>2ffd4919451824364820657fe5fa13fe</gtr:id><gtr:otherNames>Wilson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>577a76e9040530.33493753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35C3D42F-B0D0-400A-9D49-AFB7B784DE0F</gtr:id><gtr:title>The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation.</gtr:title><gtr:parentPublicationTitle>Radiation oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa053970968e15a89fb5d44c359aa14f"><gtr:id>aa053970968e15a89fb5d44c359aa14f</gtr:id><gtr:otherNames>Carrington R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1748-717X</gtr:issn><gtr:outcomeId>56571e39cc0277.61364041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5ACC2FC-CAD8-4323-811E-92B2055905C0</gtr:id><gtr:title>A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.</gtr:title><gtr:parentPublicationTitle>BMC cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f9eb5874598318716f5848b742ee71e"><gtr:id>2f9eb5874598318716f5848b742ee71e</gtr:id><gtr:otherNames>Holyoake DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2407</gtr:issn><gtr:outcomeId>585d3be79dbf21.06395210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B37C87F-4C50-452C-B517-3B36C24D69CF</gtr:id><gtr:title>PO-0706: Individualised margin calculations for different target regions in anal cancer IMRT</gtr:title><gtr:parentPublicationTitle>Radiotherapy and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67c445850795fb8e638deed0d5e78bc9"><gtr:id>67c445850795fb8e638deed0d5e78bc9</gtr:id><gtr:otherNames>Durrant L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a0c04da35431.64694426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0ECB302-BC5E-472B-81C2-6F3C7415178E</gtr:id><gtr:title>NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e1cd243ee5a92b5cfb11d830864884"><gtr:id>d9e1cd243ee5a92b5cfb11d830864884</gtr:id><gtr:otherNames>Mukherjee S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>58a5bce74c91d7.90999933</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBB4B548-7190-4A45-8884-B8EFE5B547FB</gtr:id><gtr:title>Challenges in implementing model-based phase I designs in a grant-funded clinical trials unit.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0185a66de16527b15346101ee169f48a"><gtr:id>0185a66de16527b15346101ee169f48a</gtr:id><gtr:otherNames>Frangou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5a63d2917db242.39800554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B812FDAF-9CC5-42F7-84E9-C59F97E45D70</gtr:id><gtr:title>Poster_SBRT for oligometastases in the central chest appears safe and effective</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c60c4f07b590f8fe1e7feacdba0e22e0"><gtr:id>c60c4f07b590f8fe1e7feacdba0e22e0</gtr:id><gtr:otherNames>Holyoake DLP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>582ef63adbb599.49423210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23F185A8-D837-48F1-A576-C4BD678F4BA5</gtr:id><gtr:title>Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aef1af04dabf63c186701dfeb035071e"><gtr:id>aef1af04dabf63c186701dfeb035071e</gtr:id><gtr:otherNames>Leszczynska KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5a995e994ba670.10446893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>531D7D50-43B6-46AA-A33C-A90785F56AB2</gtr:id><gtr:title>NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma</gtr:title><gtr:parentPublicationTitle>JOURNAL OF CLINICAL ONCOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a66c39d4c434ca09aec051066a82ce77"><gtr:id>a66c39d4c434ca09aec051066a82ce77</gtr:id><gtr:otherNames>Mukherjee Somnath</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>578642c65f3659.10785006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7F7CEEE-53BA-4F76-8313-1F54278EA8BD</gtr:id><gtr:title>PO-0700: Fluoromisonidazole-PET/CT in pancreatic cancer: moving towards hypoxic biological target volume definition</gtr:title><gtr:parentPublicationTitle>Radiotherapy and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e72e51aacbce037a98004577c2bfe94f"><gtr:id>e72e51aacbce037a98004577c2bfe94f</gtr:id><gtr:otherNames>Wilson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a0bed25985b2.21082813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF540879-D5A9-4006-B97E-BCD943D0E16C</gtr:id><gtr:title>Abstract_Patient and tumour characteristics impacting on lymph node metastases rate (LNMR) in squamous cell carcinoma of the anal canal and margin (SCCA) using data from the NCRI randomised phase III ACT II trial: implications for radiotherapy target volume Anal Cancer</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e530190a19bc158f6b8ef9c877bc6cb"><gtr:id>5e530190a19bc158f6b8ef9c877bc6cb</gtr:id><gtr:otherNames>Gynne-Jones R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56a0c205462611.75470287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92D30CFC-77E1-4E06-85CB-9DE5B78688F5</gtr:id><gtr:title>A tumor control probability model for anal squamous cell carcinoma.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eed8d902a99f5f922410822a358cf14c"><gtr:id>eed8d902a99f5f922410822a358cf14c</gtr:id><gtr:otherNames>Muirhead R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>56571b3a321947.27348401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9555AF1-DB97-46F2-A800-B746A392906E</gtr:id><gtr:title>Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET).</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32c740640acc8cc4ac97df2b6e965c2a"><gtr:id>32c740640acc8cc4ac97df2b6e965c2a</gtr:id><gtr:otherNames>Harrington K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>59e5f921a51656.97805287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B202BE2-5F58-463D-ABA5-9F4DC802000E</gtr:id><gtr:title>The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus</gtr:title><gtr:parentPublicationTitle>International Journal of Radiation Oncology*Biology*Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45f370758702188a47f5cbc6020a1f31"><gtr:id>45f370758702188a47f5cbc6020a1f31</gtr:id><gtr:otherNames>Sebag-Montefiore D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>58074b983a6e73.39748162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0A9CF6D-D2AD-440F-9A26-CA6CC1853A4C</gtr:id><gtr:title>An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton Planning.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f822086bb4508bdbae8e47200941e6bc"><gtr:id>f822086bb4508bdbae8e47200941e6bc</gtr:id><gtr:otherNames>Warren S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>56cae90cde21f2.89284484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4120B499-BDF5-427A-B63F-0D7F035DB6B7</gtr:id><gtr:title>PO-0712: Biological target volume definition in locally advanced pancreatic cancer: how useful is FDG-PET?</gtr:title><gtr:parentPublicationTitle>Radiotherapy and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e72e51aacbce037a98004577c2bfe94f"><gtr:id>e72e51aacbce037a98004577c2bfe94f</gtr:id><gtr:otherNames>Wilson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56a0ea283da991.46895829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5BA48A5-251A-4324-9BF7-45AEC125FC3C</gtr:id><gtr:title>Impact of Weight Change on Dose Delivery in Pancreatic Intensity Modulated Radiation Therapy</gtr:title><gtr:parentPublicationTitle>International Journal of Radiation Oncology*Biology*Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9da1e41f28473e556d4091c8d0380686"><gtr:id>9da1e41f28473e556d4091c8d0380686</gtr:id><gtr:otherNames>Chu K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56a0da86a493b5.73133277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16A113B6-FA63-4791-8F50-0F4D2AF95DDB</gtr:id><gtr:title>On-trial radiotherapy quality assurance in NeoSCOPE: A randomised phase II trial of chemoradiotherapy in oesophageal cancer</gtr:title><gtr:parentPublicationTitle>JOURNAL OF CLINICAL ONCOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6935932a0541069093d6efc5407b5036"><gtr:id>6935932a0541069093d6efc5407b5036</gtr:id><gtr:otherNames>Evans Elin</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>578642341645b3.00305240</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7ABC245-918A-44BE-B359-431F5650E20A</gtr:id><gtr:title>Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes.</gtr:title><gtr:parentPublicationTitle>The British journal of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e711961f4a7b3671e24dd3d15bd45382"><gtr:id>e711961f4a7b3671e24dd3d15bd45382</gtr:id><gtr:otherNames>Beyond TME Collaborative</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1323</gtr:issn><gtr:outcomeId>5461ec2366d726.63065538</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7F7AFBF-011C-4F46-B8E6-2B4450F00E9F</gtr:id><gtr:title>Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT).</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67c445850795fb8e638deed0d5e78bc9"><gtr:id>67c445850795fb8e638deed0d5e78bc9</gtr:id><gtr:otherNames>Durrant L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5a995e070e4ee1.52681427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A470ED74-FCD5-489B-9C90-F2517D23EAFB</gtr:id><gtr:title>Abstract_Role of neo-adjuvant radiotherapy in rectal cancer - less is more?</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a54eaa1a0d0815991a62fdc90faa965e"><gtr:id>a54eaa1a0d0815991a62fdc90faa965e</gtr:id><gtr:otherNames>Qamar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a0be4901c8a2.71318372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08003B1B-49CB-4FC6-8B3B-5765C0FA4F6F</gtr:id><gtr:title>Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f9eb5874598318716f5848b742ee71e"><gtr:id>2f9eb5874598318716f5848b742ee71e</gtr:id><gtr:otherNames>Holyoake DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5821d1fff33c32.53001355</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3DA2A21-A115-40D4-8307-76B9E7B70ECF</gtr:id><gtr:title>Stereotactic body radiotherapy for liver metastases.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9a0e40dc2ca1043ee8783b3e83506fe"><gtr:id>c9a0e40dc2ca1043ee8783b3e83506fe</gtr:id><gtr:otherNames>Aitken KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>doi_55f985985e14e23b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11306B25-B8FF-4384-8AA7-C4565DF07ECF</gtr:id><gtr:title>Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c349ab99087a0dcd1a400fc417f8e96"><gtr:id>8c349ab99087a0dcd1a400fc417f8e96</gtr:id><gtr:otherNames>Robinson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>56571a38c860c7.06922917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7298E517-64D8-4996-A06A-A99161349679</gtr:id><gtr:title>SU-F-T-108: Texture Analysis for Toxicity Prediction From Dose Surface Maps</gtr:title><gtr:parentPublicationTitle>Medical Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4eb6ff4c2a1ad14391659fb5de69530"><gtr:id>a4eb6ff4c2a1ad14391659fb5de69530</gtr:id><gtr:otherNames>Witztum A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>587782e9a903a6.49769229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3312300B-CFC0-46BC-AFEF-AAC83A1B7042</gtr:id><gtr:title>ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)-Mechanism and clinical outcomes</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ffd4919451824364820657fe5fa13fe"><gtr:id>2ffd4919451824364820657fe5fa13fe</gtr:id><gtr:otherNames>Wilson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56cb03cfc91d39.58602076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA02F211-CCB2-44F9-865F-33F9566CF933</gtr:id><gtr:title>NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>BMC cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e1cd243ee5a92b5cfb11d830864884"><gtr:id>d9e1cd243ee5a92b5cfb11d830864884</gtr:id><gtr:otherNames>Mukherjee S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2407</gtr:issn><gtr:outcomeId>doi_55f985985e1e676c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D7C20D8-120D-47E2-A58B-1FFAE534AB2F</gtr:id><gtr:title>Normal tissue sparing with respiratory adapted volumetric modulated arc therapy for distal oesophageal and gastro-oesophageal tumours.</gtr:title><gtr:parentPublicationTitle>Acta oncologica (Stockholm, Sweden)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/566a8fb06bce367abce4873aa6ee6073"><gtr:id>566a8fb06bce367abce4873aa6ee6073</gtr:id><gtr:otherNames>Hafeez S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0284-186X</gtr:issn><gtr:outcomeId>5461ed7016f5c2.17301482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C8443B2-8304-4127-B30A-888E7FC7E29D</gtr:id><gtr:title>Correlation ofF-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ffd4919451824364820657fe5fa13fe"><gtr:id>2ffd4919451824364820657fe5fa13fe</gtr:id><gtr:otherNames>Wilson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>58a5bbbc2d82b4.32817585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>346B1A66-104D-4EF8-99F0-73CE80CB4252</gtr:id><gtr:title>Abstract_Patient and tumor characteristics impacting on lymph node metastases rate (LNMR) in squamous cell carcinoma of the anal canal and margin (SCCA) using data from the NCRI randomized phase III ACT II trial: Implications for radiotherapy target volume</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14ad1c610691988859aedc8dccd1419c"><gtr:id>14ad1c610691988859aedc8dccd1419c</gtr:id><gtr:otherNames>Glynne-Jones R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56a0e2c75a0933.93661821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CA7AB0E-57F8-402B-9513-91F404A12096</gtr:id><gtr:title>EP-1474: The dosimetric effect of interfraction motion on the duodenum in pancreatic radiotherapy</gtr:title><gtr:parentPublicationTitle>Radiotherapy and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4eb6ff4c2a1ad14391659fb5de69530"><gtr:id>a4eb6ff4c2a1ad14391659fb5de69530</gtr:id><gtr:otherNames>Witztum A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a0c0c5d3c072.84579458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA6893DC-4513-46F9-94BF-7C88C6E2DA01</gtr:id><gtr:title>Comparison of deliverable IMRT and VMAT for spine metastases using a simultaneous integrated boost.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e3c802e820f0e64574613d76cc0c194"><gtr:id>6e3c802e820f0e64574613d76cc0c194</gtr:id><gtr:otherNames>Lee YK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>5461ee6aad9b10.49570953</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A3C820A-0C31-499D-8C1D-222E0F85A300</gtr:id><gtr:title>Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f822086bb4508bdbae8e47200941e6bc"><gtr:id>f822086bb4508bdbae8e47200941e6bc</gtr:id><gtr:otherNames>Warren S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>5461e8d6165132.15163398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C85AAB92-2A94-4EF0-B49C-99A933CF8A92</gtr:id><gtr:title>UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1862e7eb5dbeb6bd85f37db0f3a0fb0f"><gtr:id>1862e7eb5dbeb6bd85f37db0f3a0fb0f</gtr:id><gtr:otherNames>Hanna GG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5a7312a40d1623.27268553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CB8E34A-D2A6-461A-9505-589B232DFAF7</gtr:id><gtr:title>EP-1479: NTCP modeling of acute hematologic toxicity in conformal and intensity-modulated radiotherapy in anal cancer</gtr:title><gtr:parentPublicationTitle>Radiotherapy and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c349ab99087a0dcd1a400fc417f8e96"><gtr:id>8c349ab99087a0dcd1a400fc417f8e96</gtr:id><gtr:otherNames>Robinson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a0c144d872b5.04093507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD0BE96E-6687-4178-AEC6-26B684EE9270</gtr:id><gtr:title>Personalized Dose Escalation in Anal Cancer</gtr:title><gtr:parentPublicationTitle>International Journal of Radiation Oncology*Biology*Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c349ab99087a0dcd1a400fc417f8e96"><gtr:id>8c349ab99087a0dcd1a400fc417f8e96</gtr:id><gtr:otherNames>Robinson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>58074b98800215.95669052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B46E5B3-F3CD-46C5-96F1-5944F715F212</gtr:id><gtr:title>PD-0408: Recalculating AAA plans with Acuros XB for oesophageal cancer - are we getting closer to the &amp;quot;truth&amp;quot;?</gtr:title><gtr:parentPublicationTitle>Radiotherapy and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e17c4c50c94c89774aa1434572d3e6"><gtr:id>e0e17c4c50c94c89774aa1434572d3e6</gtr:id><gtr:otherNames>Padmanaban S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56a0e48b79a476.08937225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10F06B4A-DD48-4087-8613-194CE6F692FF</gtr:id><gtr:title>Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f822086bb4508bdbae8e47200941e6bc"><gtr:id>f822086bb4508bdbae8e47200941e6bc</gtr:id><gtr:otherNames>Warren S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>5a7b01fd98ef09.00023857</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>875F9AB7-39DF-46E3-914B-CE96AA70FEAA</gtr:id><gtr:title>The role of radiotherapy and chemoradiation in the management of primary liver tumours.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9a0e40dc2ca1043ee8783b3e83506fe"><gtr:id>c9a0e40dc2ca1043ee8783b3e83506fe</gtr:id><gtr:otherNames>Aitken KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5461e910525135.54891601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>581AF790-E8AB-4338-837A-C81E679E6897</gtr:id><gtr:title>Cone beam CT verification for active breathing control (ABC)-gated radiotherapy for lung cancer.</gtr:title><gtr:parentPublicationTitle>Acta oncologica (Stockholm, Sweden)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ece72ce1d0bd8d5309f290c104f07d8"><gtr:id>8ece72ce1d0bd8d5309f290c104f07d8</gtr:id><gtr:otherNames>Yeoh KW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0284-186X</gtr:issn><gtr:outcomeId>5461ebe511c785.94149811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A378DACC-A06F-4E36-BC30-A401E54E2106</gtr:id><gtr:title>The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ffd4919451824364820657fe5fa13fe"><gtr:id>2ffd4919451824364820657fe5fa13fe</gtr:id><gtr:otherNames>Wilson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5461e743cdf0b9.55617280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0091A63-9470-44FA-B4B0-AED7E821A27C</gtr:id><gtr:title>Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.</gtr:title><gtr:parentPublicationTitle>Frontiers in oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68b844e97c988ac9c71765232daa902e"><gtr:id>68b844e97c988ac9c71765232daa902e</gtr:id><gtr:otherNames>O'Cathail SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2234-943X</gtr:issn><gtr:outcomeId>598b27d6bd73c8.80647674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>288AEB70-FBC7-4FBA-AC08-8050BDD356FB</gtr:id><gtr:title>Oral presentation_An analysis of plan robustness for oesophageal tumours: comparing RapidArc and spot scanning proton therapy</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f822086bb4508bdbae8e47200941e6bc"><gtr:id>f822086bb4508bdbae8e47200941e6bc</gtr:id><gtr:otherNames>Warren S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a0b6ef5f63d9.27726774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D032ECDC-3C7C-4F3B-8DF5-822829E9C9DC</gtr:id><gtr:title>Abstract_As Stereotactic body radiation therapy (SBRT) for extracranial oligometastases</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bebe362687bf0d15de81b5f38e8b53b3"><gtr:id>bebe362687bf0d15de81b5f38e8b53b3</gtr:id><gtr:otherNames>Aitken K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56a0e3b14b4670.98403088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>379EC9B4-2FEA-4C3E-808A-D8A05F0D2D09</gtr:id><gtr:title>Target Volume Delineation and Treatment Planning for Particle Therapy: A Practical Guide Practical Guides in Radiation Oncology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4a5b56f68f6ee293b7ab8f394db5d93"><gtr:id>c4a5b56f68f6ee293b7ab8f394db5d93</gtr:id><gtr:otherNames>Plastaras JP.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:isbn>9783319424774</gtr:isbn><gtr:outcomeId>58497fe33a2020.27840473</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12001/2</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>006DC612-6329-4D37-A540-5FB2CA634720</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>